Overview
Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.
Background
Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.
Indication
Diosmin is used over-the-counter alone or with ingredients such as hesperidin and diosmetin to support vein and capillary function.
Associated Conditions
- Capillary fragility
- Circulatory Function
- Haemorrhoids
- Venous Insufficiency
- Healthy capillaries
- Healthy veins
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/12/31 | N/A | ENROLLING_BY_INVITATION | Ankara Etlik City Hospital | ||
2024/09/05 | Phase 3 | Recruiting | Pirogov Russian National Research Medical University | ||
2024/08/09 | Phase 1 | Recruiting | Sadat City University | ||
2024/03/19 | N/A | Not yet recruiting | |||
2023/10/16 | Phase 4 | Not yet recruiting | |||
2023/07/12 | Phase 3 | Recruiting | |||
2023/03/06 | Phase 3 | Recruiting | |||
2023/01/04 | Phase 3 | Recruiting | |||
2022/11/23 | Phase 3 | Recruiting | |||
2021/06/22 | Not Applicable | Completed | Pirogov Russian National Research Medical University |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Primus Pharmaceuticals, Inc. | 68040-610 | ORAL | 600 mg in 1 1 | 2/24/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| DAFLON TABLET 500 mg | SIN01067P | TABLET, SUGAR COATED | 450 mg | 5/12/1988 | |
| DAFLON FILM-COATED TABLET 1000 mg | SIN15669P | TABLET, FILM COATED | 900 mg | 4/16/2019 | |
| DAVMORID FILM COATED TABLET | SIN16960P | TABLET, FILM COATED | 450mg | 2/20/2024 | |
| RUVENTIN FILM COATED TABLET 500MG | SIN16068P | TABLET, FILM COATED | 450mg | 12/29/2020 | |
| DIOSPER FILM COATED TABLET | SIN11942P | TABLET, FILM COATED | 450 mg | 5/21/2002 | |
| VESSOSMIN FILM COATED TABLET 500MG | SIN17191P | TABLET, FILM COATED | 450mg | 3/4/2025 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Diosming Tablets | 国药准字H20058471 | 化学药品 | 片剂 | 7/14/2020 | |
| Diosming Tablets | 国药准字H20066737 | 化学药品 | 片剂 | 1/13/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| DAFLON TABLETS 1000MG | N/A | servier hong kong limited | N/A | N/A | 4/26/2023 |
| DIOFLEX TAB | N/A | N/A | N/A | 6/17/2004 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||